Integral Health Asset Management’s Keros Therapeutics KROS Stock Holding History

Integral Health Asset Management’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-450,000	Closed	-$7.12M	–	97
2024 Q4	$7.12M	Buy	450,000 +250,000	+125%	+$13M	0.61%	53
2024 Q3	$11.6M	Buy	200,000 +115,000	+135%	+$5.68M	1.31%	23
2024 Q2	$3.88M	Buy	85,000 +45,000	+113%	+$2.42M	0.37%	59
2024 Q1	$2.65M	Buy	+40,000	New	+$2.37M	0.25%	78
2023 Q3	–	Sell	-52,000	Closed	-$2.09M	–	81
2023 Q2	$2.09M	Buy	52,000 +2,000	+4%	+$87.7K	0.26%	68
2023 Q1	$2.13M	Sell	50,000 -10,000	-17%	-$505K	0.43%	60
2022 Q4	$2.88M	Buy	+60,000	New	+$2.8M	0.6%	51
2022 Q2	–	Sell	-81,000	Closed	-$4.41M	–	78
2022 Q1	$4.41M	Buy	81,000 +46,000	+131%	+$2.36M	1.15%	34
2021 Q4	$2.05M	Buy	+35,000	New	+$1.75M	0.57%	53

Other funds holding KROS

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Integral Health Asset Management's KROS Position: Q1 2025 in Review

Integral Health Asset Management sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 450,000 shares — an estimated $7.12M sold.

Integral Health Asset Management first reported a position in KROS in Q4 2021 and held it in 9 quarters. The position peaked at $11.6M in Q3 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

Integral Health Asset Management reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
Integral Health Asset Management sold 450,000 Keros Therapeutics shares in Q1 2025, an estimated $7.12M.
Integral Health Asset Management first reported a position in Keros Therapeutics in Q4 2021 and held it in 9 quarters.
Integral Health Asset Management's Keros Therapeutics position peaked at $11.6M in Q3 2024.
156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on Integral Health Asset Management's 13F filing for Q1 2025, filed 15 May 2025.